The Global Burden of asthma. Chest. 2006; 130 (1 Suppl.):4S–12S. .
British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on Management of Asthma. 05/08. Available at: http://www.brit-thoracic.org.uk (accessed 30 April 2009).
Global Initiative for Asthma Guidelines 11/06. Available at: http://www.ginasthma.com (accessed 30 April 2009).
et al. Severe asthma: what are the important questions? J Allergy Clin Immunol 2008; 119:1337–48. , ,
Proceedings of the ATS Workshop on Refractory Asthma. Current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162:2341–51.
et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218–24. , ,
et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715–21. , ,
et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483–94. , ,
Anti-TNF-α in asthma. J Allergy Clin Immunol 2008; 121:5–10. , , .
Asthma treatment: ‘magic bullets which seek their own targets’. Allergy 2007; 62:605–10. , , , , .
Anti-IgE for chronic asthma in adults and children. Cochrane Database of Systematic Reviews, 2006, Issue 2. Art. no.: CD003559. DOI: 10.1002/14651858.CD003559.pub3. , , , , .
Eosinophils in asthma and other allergic diseases. Br Med Bull 2000; 56:985–1003. , , , , .
et al. A critical role for eosinophils in allergic airways remodelling. Science 2004; 305:1776–9. , ,
New insights into the relationship between airway inflammation and asthma. Clin Sci (Lond) 2002; 103:201–11. , , , , , .
New insights into the role of the mast cell in asthma. Clin Exp Allergy 2003; 33:550–6. , , , .
Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 2007; 119:1043–52. , .
Novel targets of therapy in asthma. Curr Opin Pulm Med 2009; 15:63–71. .
et al. Differences in airway remodelling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005; 166:544–9. , ,
Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. J Allergy Clin Immunol 2006; 118:331–6. , .
T cell trafficking in allergic asthma: the ins and outs. Annu Rev Immunol 2008; 26:205–32. , , .
The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003; 111:450–63. , , .
et al. Predominant TH-2 like bronchoalveolar T-lymphocyte populations in atopic asthma. N Engl J Med 1992; 326:298–304. , ,
Th2 cytokine expression in bronchoalveolar lavage fluid T-lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2002; 110:899–905. , , , , , .
Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003; 33:1711–6. , , , , , .
et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008; 121:685–91. , ,
Relationship between bronchial mucosal IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997; 156:704–8. , , , , , .
et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 1997; 99:657–65. , ,
Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. J Clin Invest 1991; 88:1048–53. , .
et al. Granulocyte macrophage colony stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD. Thorax. 2009 Thorax Online First, published 12 February 2009 as 10.1136/thx.2008.108290, ,
et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282:2261–3. , ,
et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779–88. , ,
Granulocyte–macrophage colony stimulating factor is required for bronchial eosinophilia in a murine model of allergic airway inflammation. J Immunol 2008; 180:2600–7. , , , , .
et al. TNF alpha mRNA expression in allergic inflammation. Clin Exp Allergy 1991; 21:745–50. , ,
et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10:471–80. , ,
et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012–8. , ,
et al. Evidence of a role of tumour necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354:697–708. , ,
Mast cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346:1699–705. , , , , , .
Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002; 19:879–85. , , .
et al. Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. FASEB J 2003; 17:2139–41. , ,
et al. Bronchial inflammation and airway responses to deep inspiration in asthma and COPD. Am J Respir Crit Care Med 2007; 176:121–8. , ,
et al. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol 2008; 122:335–41. , ,
The extracellular deposition of mast cell products is increased in hypertrophic airways smooth muscles in allergic asthma but not in nonallergic asthma. Allergy 2005; 60:1241–7. , , , .
Microlocalisation of inflammatory cells and structural cells: functional consequences in airways disease. Eur Respir J 2007; 30:1043–56. , .
et al. IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol 2003; 140:1159–62. , ,
et al. Direct effects of interleukin-13 on signalling pathways for physiological responses in cultured human airway smooth muscle cells. Am J Respir Crit Care Med 2001; 164:141–8. , ,
et al. IL-13 dependent autocrine signalling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2002; 282:520–8. , ,
et al. Mast cells promote airway smooth muscle cell differentiation via autocrine upregulation of TGF-β1. J Immunol 2008; 181:5001–7. , ,
Severe asthma in adults. Am J Resp Crit Care Med 2005; 172:149–60. .
Is the neutrophil the key effector cell in severe asthma? Thorax 2005; 60:529–30. , , , .
Azithromycin therapy for neutrophilic airways disease: myth or magic? Thorax 2009; 64:186–9. , , , , .
Airway structural alterations selectively associated with severe asthma. Am J Resp Crit Care Med 2003; 167:1360–8. , , , , .
et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144–8. , ,
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199–204. , , , .
et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study [abstract. Am J Respir Crit Care Med 2003; 167:1655–9. , ,
et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062–71. , ,
et al. Meoplizumab and exacerbations of eosinophilic refractory asthma. N Engl J Med 2009; 360:973–84. , ,
et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985–93. , ,
et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029–36. , ,
et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160:1816–23. , ,
et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963–70. , ,
et al. Preclinical efficacy and safety of pascolizumab (SB240683): a humanised anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002; 130:93–100. , ,
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422–31. , , , , .
Pharmacokinetics and local tolerance of an IL-4/IL-13 antagonist inhalation powder in humans. ERS Conference 2008:545S (abstract). Available at: http://www.ersnet.org
, , , , .
et al. The effects of IMA-638 on allergen induced airway responses in subjects with mild atopic asthma. ERS Conference 2008:827S (abstract). Available at: http://www.ersnet.org
et al. A double-blind, placebo-controlled, study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma. ERS Conference 2008:515S (abstract). Available at: http://www.ersnet.org
et al. Multiple-dose study of AMG317 in adults with asthma: pharmacokinetics and safety. Am J Respir Crit Care Med 2008; 177:A568. , ,
A single dose of MEDI-528, a monoclonal antibody against interleukin-9, is well tolerated in mild and moderate asthmatics in the phase II trial MI-CP-138. Chest 2007; 132:478. , , , , , .
et al. The effects of nebulised recombinant interferon-γ in asthmatic airways. J Allergy Clin Immunol 1995; 95:133–5. , ,
Clinical and immunological effects of low-dose IFNα treatment in patients with corticosteroid-resistant asthma. Allergy 2003; 58:1250–5. , , , .
et al. Interferon-alphacon-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticoid dose. Respiration 2006; 73:566–70. , ,
et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000; 356:2149–53. , ,
et al. A randomised, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154:5492–9. , ,
et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174:753–62. , ,
The role of a soluble TNFα receptor fusion protein (Etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008; 63:584–91. , , , , , .
et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179:549–58. , ,
et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:926–34. , ,
Development and function of Th17 cells in health and disease. J Allergy Clin Immunol 2009; 123:1004–11. , , .
et al. Th-17 associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009; 123:1185–7. , ,
et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2007; 120:1234–1. , ,
Soluble ST blocks interleukin-33 signalling in allergic airway inflammation. J Biol Chem 2007; 282:26369–80. , , , .